- Exelixis has increased its full-year 2025 total revenue forecast to between $2.25 billion and $2.35 billion, up from the previous guidance of $2.15 billion to $2.25 billion.
- The expected net product revenues are now between $2.05 billion and $2.15 billion, compared to the prior range of $1.95 billion to $2.05 billion.
- Research and development (R&D) expenses are still anticipated to be between $925 million and $975 million.
- Sales, general and administrative (SG&A) expenses remain projected between $475 million and $525 million.
- In the first quarter of 2025, Exelixis reported earnings per share (EPS) of 55 cents, a significant increase from 12 cents year-over-year, and above the estimate of 37 cents.
- First-quarter total revenue was $555.4 million, a 31% increase year-over-year, beating the estimate of $495.6 million.
- Net product revenues for the first quarter reached $513.3 million, up 36% year-over-year and exceeding the expected $449.7 million.
- The leading product, Cabometyx, gained revenue of $510.9 million in the quarter, reflecting a 36% year-over-year increase and surpassing the forecast of $449.4 million.
- Meanwhile, Cometriq revenue was $2.4 million, up 14% year-over-year, though slightly under the estimate of $3.21 million.
- Total operating expenses for the quarter were $368.6 million, down 6.9% year-over-year and less than the estimated $386.8 million.
- R&D expenses were $212.2 million in the first quarter, decreasing 6.8% year-over-year, below the estimate of $240.7 million.
- The company noted the strong performance of CABOMETYX contributes to the increased financial guidance for the year’s net product revenues and total revenues.
- Exelixis is focused on achieving milestones for zanzalintinib by the second half of 2025.
- Shares of Exelixis rose 3.6% in post-market trading, reaching $38.29, with 4,014 shares traded.
- The company received 11 buy recommendations, 9 hold recommendations, and 1 sell recommendation from analysts.
Exelixis Inc on Smartkarma
Analysts on Smartkarma, like Baptista Research, are bullish on Exelixis Inc. They highlight the company’s strong financial growth and developments in their oncology portfolio. Exelixis reported impressive total revenues of approximately $567 million for the fourth quarter, largely driven by the success of their cabozantinib franchise, with CABOMETYX netting $515.2 million in product revenues. For the full year 2024, Exelixis saw significant growth with U.S. cabo franchise net product revenues hitting $1.81 billion. Baptista Research‘s report, titled “Exelixis Inc.: Pipeline Expansion & Innovation to Build A Robust Portfolio!”, emphasizes the company’s positive performance and outlook.
A look at Exelixis Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Exelixis Inc, a development-stage biotechnology company focused on discovering and developing small-molecule therapeutics for cancer and other serious diseases, has a positive long-term outlook according to Smartkarma Smart Scores. With strong scores in Growth, Resilience, and Momentum, Exelixis is positioned well for future success in the pharmaceutical industry. The company’s strategic alliances with other pharmaceutical and biotechnology firms further enhance its potential for growth and innovation.
While Exelixis Inc scored lower in Value and Dividend factors, its high scores in Growth, Resilience, and Momentum indicate a promising trajectory in the long run. As the company continues to build its portfolio of compounds with pharmaceutical potential, investors may see opportunities for significant returns. With a clear dedication to research and development in the healthcare sector, Exelixis remains an intriguing player to watch in the coming years.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
